Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Christmas comfort over COVID vaccines collides with new curbs

Published 12/18/2020, 06:45 AM
Updated 12/18/2020, 08:01 AM
© Reuters. A coronavirus disease (COVID-19) positive patient, at Trinitas Regional Medical Center in Elizabeth, New Jersey

By Alistair Smout

LONDON (Reuters) - Coronavirus vaccine approvals and rollouts have brought comfort and joy to many this Christmas but failed to halt new curbs on travel and family gatherings as COVID-19 cases rise worldwide.

More than 73.68 million people have been reported to be infected by the coronavirus globally and 1,655,424​ have died, according to a Reuters tally, with the United States leading the way in the number of deaths and infections.

A fast-spreading U.S. surge is pushing hospitals to the brink, weeks after millions took to the air and roads for the Thanksgiving holiday, with admissions rising to record heights for a 19th straight day.

Now many countries are preparing for the Christmas rush, with travel plans for thousands of Australians thrown into chaos when states and territories imposed border restrictions after 28 COVID-19 cases were detected in Sydney.

Large areas of England will be added to the "very high alert" COVID-19 tier category this weekend, placing residents under the most stringent curbs even as the government tries to defend a plan to relax curbs for five days over Christmas.

"It doesn't look like the tier system is holding the epidemic wave back, unfortunately" John Edmunds, a member of the government's Scientific Advisory Group for Emergencies, told Sky News.

"I think we are going to have to look at these measures and perhaps tighten them up."

South Korea, praised worldwide for its handling of the pandemic in its early stages, reported 1,062 new cases on Friday, its second-highest ever daily tally, as the government agonised over tighter restrictions.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Austrians abroad were heading home early for Christmas ahead of new quarantine rules coming in on Saturday. The country is going into a third lockdown after Christmas, the national news agency APA reported on Friday.

'NO SAFE PLACE'

Swiss Health Minister Alain Berset will ask cabinet colleagues on Friday to close restaurants for a month, two newspapers reported.

The Spanish capital of Madrid, one of Europe's worst COVID-19 hotspots at the start of the pandemic, has progressively reduced its spread without closing down clubs or shops.

But with an average notification rate of 244 cases per 100,000 inhabitants over the last 14 days, the region is back to levels seen before the second wave started.

Police in Lithuania were planning to set up roadblocks to enforce a lockdown.

"There is no safe place in Lithuania," Prime Minister Ingrida Simonyte told reporters last week.

As government leaders across the world address their nations on how to fight the pandemic, U.S. President Donald Trump has been largely silent, with his critics accusing him of abrogating his responsibilities as cases soar.

French President Emmanuel Macron tested positive for the coronavirus on Thursday, prompting a track-and-trace effort across Europe following his numerous meetings with EU heads of government.

EU states will start vaccinations against COVID-19 on Dec. 27 as Europe tries to catch up with Britain and the United States after what some have criticised as a slow EU approval process for the shots.

The European Union has been waiting for the European Medicines Agency (EMA) to approve a vaccine from Pfizer Inc (NYSE:PFE) and German partner BioNTech SE (NASDAQ:BNTX). The EMA is expected to make an announcement on Dec. 21.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The U.S. Food and Drug Administration will "rapidly" work towards granting emergency approval of Moderna (NASDAQ:MRNA) Inc's COVID-19 vaccine candidate, FDA Commissioner Stephen Hahn said on Thursday.

A panel of outside advisers to the FDA overwhelmingly endorsed the emergency use the vaccine, virtually assuring a second option for protection.

Last week, the same panel backed the Pfizer vaccine, leading to an FDA emergency use authorisation a day later.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.